[1]Fan Y, Zhou JY, Zhao Y, et al. Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAFV600E mutation-positive metastatic non-small cell lung cancer[J]. Transl Lung Cancer Res. 2024; 13(12): 3382-3391.
[2]中国抗癌协会肺癌专业委员会. 中国晚期非小细胞肺癌 BRAF 突变诊疗专家共识[J]. 中华肿瘤杂志. 2023, 45(4): 279-290.
[3]Mu YX, YANG K, Hao XZ, et al. Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated nonsmall cell lung cancer[J]. Front Oncol, 2020, 10: 603.
[4]Couraud S, Barlesi F, Fontaine-deraluelle C, et al. Clinical outcomes of non-small cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study[J]. Eur J Cancer, 2019, 116: 86-97.
[5]Guisier F, Dubos-Arvis C, Vinas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with
advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018[J]. J Thorac Oncol, 2020, 15(4): 628-636.
[6]Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8): 1321-1328.
[7]赵媛媛, 周建英, 范云, 等. BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志. 2021, 31(12): 1145-1152.
